title: Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis.
abstract: BACKGROUND
  Angiogenesis, the development of new blood vessels from pre-existing vasculature, is a prerequisite for tumor growth and metastasis. Surrogate markers for angiogenesis would be useful for studying the effectiveness of antiangiogenesis drugs. We examined the potential of three serum glycoproteins-vascular cell adhesion molecule-1 (VCAM-1), endothelial selectin (E-selectin), and von Willebrand factor (VWF)-to serve as markers for angiogenesis.
  
  
  METHODS
  Preoperative serum levels of VCAM-1, E-selectin, and VWF were measured by enzyme-linked immunosorbent assay in 93 women with early breast cancer and were compared with microvessel density in each tumor, histologic features, and recurrence after surgery. Serum samples were taken from 55 women with advanced breast cancer who were commencing hormonal therapy, both immediately before therapy and 3 months later. Changes in serum levels of VCAM-1, E-selectin, and VWF were compared with the response of the disease to hormonal therapy assessed 6 months after the start of hormone therapy or at disease progression. All P: values are two-sided.
  
  
  RESULTS
  In women with early breast cancer, serum levels of VCAM-1 (but not of E-selectin or VWF) correlated closely with microvessel density in tumors (r =.65; P:<.001), and women who developed early recurrence had higher preoperative levels of serum VCAM-1 than those who remained disease free (P: =.01). Serum VCAM-1 levels rose in women with advanced breast cancer whose disease progressed (P:<.001) but remained unchanged or fell in women with advanced breast cancer whose disease remained stable or showed a partial response to hormonal therapy.
  
  
  CONCLUSIONS
  Serum VCAM-1 appears to be a surrogate marker of angiogenesis in breast cancer. Its measurement may, therefore, help in the assessment of antiangiogenesis drugs currently in phase II trials.
authors.affiliation: Department of Academic Surgery, University Hospital of South Manchester, U.K.
authors.forename: G J
authors.initials: GJ
authors.lastname: Byrne
authors.forename: A
authors.initials: A
authors.lastname: Ghellal
authors.forename: J
authors.initials: J
authors.lastname: Iddon
authors.forename: A D
authors.initials: AD
authors.lastname: Blann
authors.forename: V
authors.initials: V
authors.lastname: Venizelos
authors.forename: S
authors.initials: S
authors.lastname: Kumar
authors.forename: A
authors.initials: A
authors.lastname: Howell
authors.forename: N J
authors.initials: NJ
authors.lastname: Bundred
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000098:blood supply* / Q000188:drug therapy / Q000601:surgery; D018450:Disease Progression; D019040:E-Selectin / Q000097:blood*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000097:blood*; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D013997:Time Factors; D016896:Treatment Outcome; D019010:Vascular Cell Adhesion Molecule-1 / Q000097:blood*; D014841:von Willebrand Factor / Q000378:metabolism*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D019040:E-Selectin; D019010:Vascular Cell Adhesion Molecule-1; D014841:von Willebrand Factor